Difficulty: Medium
Average Score: 87%
Practice
The recommended long-term antithrombotic therapy for a patient with a DVT in their leg is:
Correct answer
D
Rationale
In the context of treating a deep vein thrombosis (DVT) in the leg, the recommended long-term antithrombotic therapy is a direct factor Xa inhibitor, which is option D. Direct factor Xa inhibitors like rivaroxaban, apixaban, or edoxaban have become preferred agents due to their efficacy, safety, and convenience compared to older agents like warfarin. These medications directly inhibit factor Xa in the coagulation cascade, preventing the formation of thrombin and subsequent clot propagation.
Option A, low-molecular-weight heparin, is commonly used initially in the acute treatment of DVT but is not recommended for long-term therapy due to the need for subcutaneous injections and monitoring. Option B, warfarin tapered monthly, is no longer the first-line option for long-term anticoagulation due to its narrow therapeutic window, interactions with food and other medications, and the need for frequent monitoring.
Option C, aspirin 325 mg daily, is not recommended as the sole therapy for DVT as it is an antiplatelet agent rather than a direct anticoagulant, and its efficacy in preventing DVT extension or recurrence is limited.
In an educational context, understanding the rationale behind selecting the appropriate antithrombotic therapy for DVT is crucial for healthcare professionals managing patients with thrombotic disorders. It is essential to stay updated on current guidelines and evidence-based practices to provide optimal care and prevent complications in patients with DVT.
Option A, low-molecular-weight heparin, is commonly used initially in the acute treatment of DVT but is not recommended for long-term therapy due to the need for subcutaneous injections and monitoring. Option B, warfarin tapered monthly, is no longer the first-line option for long-term anticoagulation due to its narrow therapeutic window, interactions with food and other medications, and the need for frequent monitoring.
Option C, aspirin 325 mg daily, is not recommended as the sole therapy for DVT as it is an antiplatelet agent rather than a direct anticoagulant, and its efficacy in preventing DVT extension or recurrence is limited.
In an educational context, understanding the rationale behind selecting the appropriate antithrombotic therapy for DVT is crucial for healthcare professionals managing patients with thrombotic disorders. It is essential to stay updated on current guidelines and evidence-based practices to provide optimal care and prevent complications in patients with DVT.